MX351471B - Derivados de piridinona y pirimidinona como inhibidores del factor xia. - Google Patents

Derivados de piridinona y pirimidinona como inhibidores del factor xia.

Info

Publication number
MX351471B
MX351471B MX2014007269A MX2014007269A MX351471B MX 351471 B MX351471 B MX 351471B MX 2014007269 A MX2014007269 A MX 2014007269A MX 2014007269 A MX2014007269 A MX 2014007269A MX 351471 B MX351471 B MX 351471B
Authority
MX
Mexico
Prior art keywords
pyridinone
factor xia
xia inhibitors
pyrimidinone derivatives
inhibitors
Prior art date
Application number
MX2014007269A
Other languages
English (en)
Other versions
MX2014007269A (es
Inventor
Ichihara Osamu
Suzuki Ryo
Courtney Steve
Yarnold Chris
Flanagan Stuart
Brace Gareth
Barker John
Gadouleau Elise
Richardson Anthony
Kondo Takashi
Imagawa Akira
Nakatani Shingo
Kouyama Sho
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1122139.7A external-priority patent/GB2497806A/en
Priority claimed from GB201217290A external-priority patent/GB201217290D0/en
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2014007269A publication Critical patent/MX2014007269A/es
Publication of MX351471B publication Critical patent/MX351471B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula general (I), sus sales y N-óxidos, y solvatos y profármacos de los mismos (en donde los caracteres son como se definen en la descripción). Los compuestos de la fórmula general (I) son inhibidores del Factor XIa de manera que son útiles en la prevención de y/o terapia para enfermedades tromboembólicas. (ver Fórmula).
MX2014007269A 2011-12-21 2012-12-20 Derivados de piridinona y pirimidinona como inhibidores del factor xia. MX351471B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
GB201217290A GB201217290D0 (en) 2012-09-27 2012-09-27 Compounds
PCT/GB2012/053217 WO2013093484A1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors

Publications (2)

Publication Number Publication Date
MX2014007269A MX2014007269A (es) 2014-07-22
MX351471B true MX351471B (es) 2017-10-17

Family

ID=47553259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007269A MX351471B (es) 2011-12-21 2012-12-20 Derivados de piridinona y pirimidinona como inhibidores del factor xia.

Country Status (22)

Country Link
US (2) US9732085B2 (es)
EP (2) EP2794597B1 (es)
JP (2) JP6137193B2 (es)
KR (1) KR102011534B1 (es)
CN (1) CN104136431B (es)
AU (1) AU2012356374B2 (es)
BR (1) BR112014015669B1 (es)
CA (1) CA2859604C (es)
DK (1) DK2794597T3 (es)
ES (2) ES2765891T3 (es)
HU (1) HUE036010T2 (es)
IL (1) IL233154A (es)
IN (1) IN2014CN04676A (es)
MX (1) MX351471B (es)
NO (1) NO2794597T3 (es)
PH (1) PH12014501365A1 (es)
PL (1) PL2794597T3 (es)
PT (1) PT2794597T (es)
RU (1) RU2630677C2 (es)
SG (1) SG11201403402VA (es)
TW (1) TWI613199B (es)
WO (1) WO2013093484A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2534152B1 (en) 2010-02-11 2018-05-02 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
ES2562903T3 (es) * 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd Nuevo compuesto que tiene actividad inhibidora de PARP
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
IN2014CN02805A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
CN103974938B (zh) 2011-10-14 2016-11-09 百时美施贵宝公司 作为因子xia抑制剂的经取代的四氢异喹啉化合物
CN104136431B (zh) * 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
WO2013096642A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2013291098A1 (en) 2012-07-19 2015-02-05 Sumitomo Dainippon Pharma Co., Ltd. 1-(cycloalkyl-carbonyl)proline derivative
SG11201500270RA (en) 2012-08-03 2015-03-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
US9409908B2 (en) 2012-08-03 2016-08-09 Bristol-Myers Squibb Company Dihydropyridone p1 as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6154473B2 (ja) 2012-10-12 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤の結晶形
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) * 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015063093A1 (de) * 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
NO2760821T3 (es) 2014-01-31 2018-03-10
TWI688564B (zh) * 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
EP3134408B1 (en) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
CN104311537B (zh) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途
EP3197896B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN106687458B (zh) * 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
EP3231803B1 (en) 2014-12-10 2020-07-01 ONO Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
RU2649141C2 (ru) * 2015-04-20 2018-03-30 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
RU2653511C2 (ru) * 2015-07-29 2018-05-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
EP3371162B1 (en) * 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
AU2016344476B2 (en) 2015-10-29 2020-08-13 Merck Sharp & Dohme Llc Factor XIa inhibitors
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
HUE057289T2 (hu) 2016-08-31 2022-05-28 Jiangsu Hengrui Medicine Co Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
WO2018065330A1 (de) 2016-10-07 2018-04-12 Mitsubishi Hitec Paper Europe Gmbh Wärmeempfindliches aufzeichnungsmaterial
EP3305538A1 (de) 2016-10-07 2018-04-11 Mitsubishi HiTec Paper Europe GmbH Wärmeempfindliches aufzeichnungsmaterial
CN106950319B (zh) * 2017-04-20 2019-08-30 西安科技大学 一种检测特鲁曲班光学异构体含量的方法
CN109507345B (zh) * 2017-09-15 2022-08-05 万特制药(海南)有限公司 重酒石酸卡巴拉汀中间体及其杂质的分离测定方法
EP3741746A4 (en) * 2018-02-27 2020-12-16 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND MANUFACTURING PROCESS FOR IT
CN112004810B (zh) 2018-07-02 2022-04-08 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及制备方法
TWI825144B (zh) * 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
WO2020094156A1 (zh) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
TWI826599B (zh) 2018-11-30 2023-12-21 日商小野藥品工業股份有限公司 （３ｓ）－３－［２－（６－胺－２－氟吡啶－３－基）－４－氟－１ｈ－咪唑－５－基］－７－［５－氯－２－（１ｈ－四唑－１－基）苯基］－２，３－二氫吲嗪－５（１ｈ）－酮的新穎結晶
CN109836360B (zh) * 2019-03-19 2021-08-13 南京恩泰医药科技有限公司 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物
CN112028877B (zh) * 2019-06-04 2021-11-26 江西济民可信集团有限公司 烷氧吡啶酮化合物及其制备方法和用途
EP3998263A4 (en) * 2019-06-28 2023-09-06 Shanghai Jemincare Pharmaceuticals Co., Ltd. Tricyclic compound, preparation method therefor and use thereof
MX2022003649A (es) 2019-09-27 2022-06-08 Shenzhen Salubris Pharm Co Ltd Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos.
CN112778277B (zh) * 2019-11-11 2024-04-02 江西济民可信集团有限公司 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
CA3189771A1 (en) * 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
JP2024125436A (ja) * 2021-07-20 2024-09-19 小野薬品工業株式会社 イミダゾール化合物の製造方法
US20230097157A1 (en) * 2021-07-22 2023-03-30 Janssen Pharmaceutica Nv Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
CN113735770B (zh) * 2021-09-30 2023-06-06 四川大学 一种铑催化的4-苯基噁二唑酮与碳酸亚乙烯酯合成1-氨基异喹啉骨架的方法
TWI833610B (zh) * 2022-03-21 2024-02-21 大陸商上海濟煜醫藥科技有限公司 三并環類化合物製備方法及其中間體
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN116283908A (zh) * 2023-03-10 2023-06-23 合肥工业大学 一种n-芳香甲基吡啶酮类衍生物及其制备方法与应用
CN119894901A (zh) 2023-06-30 2025-04-25 深圳信立泰药业股份有限公司 一种多取代的大环化合物及其制备方法与应用
CN118406037B (zh) * 2024-06-25 2025-02-25 四川师范大学 一种三氮唑类衍生物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042675A1 (en) 1980-06-20 1981-12-30 Norton Company Method of mounting a grinding wheel on a spindle
EP0224283A3 (en) 1982-05-18 1988-09-21 University Of Florida Brain-specific drug delivery
CA1241120A (en) 1985-10-01 1988-08-23 Sami A. Aly Alternate mark inversion (ami) receiver
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
DE4407488A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Verwendung von Biphenyl- und Pyridylmethylpyridonen
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007004480A (es) 2004-10-15 2007-05-08 Astrazeneca Ab Quinoxalinas como inhibidores b raf.
ES2380632T3 (es) 2004-11-24 2012-05-17 Vertex Pharmceuticals Incorporated Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas
AR056682A1 (es) 2005-07-29 2007-10-17 Kalypsys Inc COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
US7626039B2 (en) 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
MX2009005449A (es) * 2006-11-24 2009-06-02 Takeda Pharmaceutical Compuesto heteromonociclico y uso del mismo.
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
CA2708151A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
WO2009114677A1 (en) * 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
AU2011313150A1 (en) * 2010-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1,4-oxazepane derivatives
CN104136431B (zh) * 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物

Also Published As

Publication number Publication date
MX2014007269A (es) 2014-07-22
TWI613199B (zh) 2018-02-01
JP6137193B2 (ja) 2017-05-31
AU2012356374A1 (en) 2014-07-10
BR112014015669A8 (pt) 2017-07-04
JP2015500868A (ja) 2015-01-08
SG11201403402VA (en) 2015-01-29
BR112014015669B1 (pt) 2021-10-13
US20150152112A1 (en) 2015-06-04
CA2859604C (en) 2019-12-17
EP2794597A1 (en) 2014-10-29
IL233154A0 (en) 2014-08-03
DK2794597T3 (en) 2018-01-15
PH12014501365B1 (en) 2014-09-22
BR112014015669A2 (pt) 2017-06-13
CN104136431B (zh) 2017-03-15
AU2012356374A8 (en) 2014-08-07
EP3290413A1 (en) 2018-03-07
EP3290413B9 (en) 2020-04-29
IL233154A (en) 2016-12-29
HK1198386A1 (en) 2015-04-17
EP2794597B1 (en) 2017-11-15
NO2794597T3 (es) 2018-04-14
RU2630677C2 (ru) 2017-09-12
ES2765891T3 (es) 2020-06-11
PL2794597T3 (pl) 2018-03-30
PT2794597T (pt) 2018-01-16
PH12014501365A1 (en) 2014-09-22
CN104136431A (zh) 2014-11-05
IN2014CN04676A (es) 2015-09-18
JP6447660B2 (ja) 2019-01-09
US10717738B2 (en) 2020-07-21
WO2013093484A1 (en) 2013-06-27
KR20140103286A (ko) 2014-08-26
US9732085B2 (en) 2017-08-15
HUE036010T2 (hu) 2018-06-28
JP2017160239A (ja) 2017-09-14
ES2655669T3 (es) 2018-02-21
AU2012356374B2 (en) 2017-06-22
US20170305917A1 (en) 2017-10-26
TW201339157A (zh) 2013-10-01
CA2859604A1 (en) 2013-06-27
RU2014129797A (ru) 2016-02-10
EP3290413B1 (en) 2019-11-13
NZ626176A (en) 2015-09-25
KR102011534B1 (ko) 2019-08-16

Similar Documents

Publication Publication Date Title
MX351471B (es) Derivados de piridinona y pirimidinona como inhibidores del factor xia.
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
PH12017502141A1 (en) Compounds and their methods of use
MX352975B (es) Piridina y derivados de pirazina.
PH12016501388A1 (en) Heteroaryls and uses thereof
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
GB201209587D0 (en) Therapeutic compounds
PH12015501038A1 (en) Inhibitors of iap
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
PH12015500399A1 (en) Azaindolines
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration